VC Funding Top Ten — October 6, 2026: Fusion Energy, AI Infrastructure, Biotech Breakthroughs

Overview

Tuesday afternoon, October sixth. Today's biggest check goes to Gauss Fusion, which just locked in a massive one hundred fifty million dollar Series A. We're tracking eight disclosed rounds today, with a clear theme emerging around artificial intelligence. Let's break down the numbers and the names making moves. With m

In this show

• Tuesday afternoon, October sixth. Today's biggest check goes to Gauss Fusion, which just locked in a massive one hundred fifty million dollar Series A. We're tracking eight disclosed rounds today, with a clear theme emerging around artificial intelligence. Let's break down the numbers and the names making moves. With me are our Markets and World analysts. Let's get into the deal flow.
• Here is the snapshot for today. The total disclosed venture funding reached four hundred twenty-eight million dollars across eight rounds. The largest round, as mentioned, was Gauss Fusion's one hundred fifty million dollar Series A. The hottest category was clearly AI, representing four of the top ten deals. We saw no notable IPO or M&A activity today. The story of the day is the continued capital attraction for AI-focused startups, spanning infrastructure, security, and specialized applications.
• Let's start with that top deal. Gauss Fusion raised a one hundred fifty million dollar Series A with its lead investor undisclosed. The German startup is developing a commercial fusion power plant based on the stellarator concept, aiming for clean and safe energy. This is a significant capital injection for a Series A, and the company states it's aimed at expanding operations and specifically attracting U.S. investors. It marks a major step in the private sector's global race to finally commercialize fusion energy.
• In second, RougeTx, a preclinical biotech, secured a fifty-eight million dollar Series A. The round was led by a syndicate including BioGeneration Ventures and Angelini Ventures. RougeTx is developing therapies to restore vascular integrity by targeting pericyte dysfunction. This funding is critical as it will advance the company's lead program for hereditary hemorrhagic telangiectasia, or HHT. This is a serious inherited bleeding disorder that currently has no approved therapies, representing a significant unmet medical need.
• Coming in third, developer infrastructure platform Namespace raised a forty-two million dollar Series B led by Scale Venture Partners. They provide specialized compute stacks to accelerate software engineering, particularly for AI agent development and testing. What's notable here is the velocity; this Series B comes just seven months after their Series A. This brings their total funding to sixty-five million dollars and signals incredibly strong demand for developer-focused cloud infrastructure that can handle the complex needs of modern AI workflows.
• At number four, cybersecurity firm Hadrian closed a forty million dollar Series B. The round was co-led by Forgepoint Capital International and SmartFin. Hadrian has built an agentic AI-powered offensive security platform. It helps security teams find, validate, and fix exploitable risks before malicious actors can. This new funding brings Hadrian's total raised to sixty-five million dollars. The capital is earmarked for expansion in EMEA and the U.S., a timely move as AI-driven cyber threats continue to become more prevalent and sophisticated.
• In fifth place is Clockwork.io, an AI infrastructure company, raising a thirty-one million dollar venture round. The investment was led by Premji Invest, Wing Venture Capital, and Seligman Ventures. Clockwork provides fault-tolerance software designed to prevent costly GPU downtime and, crucially, preserve the progress of AI training workloads during hardware or software failures. With their total funding now at seventy-three million dollars, Clockwork is tackling a massive pain point in the AI infrastructure market, where every second of GPU downtime translates to significant financial loss.
• At number six, we have another AI deal. WhiteLab Genomics raised a twenty-six million dollar Series B led by AVP. The company has developed an AI platform specifically for designing and optimizing the delivery systems for cell and gene therapies. This is a critical bottleneck in the development of new genomic medicines. The new funding will be used to accelerate their in vivo validation programs and to support commercial expansion. It's a clear signal of the deepening role AI is playing at the cutting edge of drug discovery and development.
• Moving to climate tech at number seven, Reclinker secured a thirteen million dollar Series A. The round was led by Clean Growth Fund and AP Ventures. This startup has developed a novel process to recycle construction and demolition waste directly into low-carbon cement. This oversubscribed round, which converts from an initial ten million pound note, will help the company commercialize a technology that could significantly decarbonize the cement industry. That's a huge target, as cement production is a major contributor to global CO2 emissions.
• And at number eight, Comparables.ai raised a six million dollar Seed round led by Pragmatech and Araya Ventures. They've built an AI-powered M&A intelligence platform for dealmakers, designed to help them discover and analyze private and public market data more efficiently. The platform is already showing strong traction, reportedly used by over fifty thousand professionals in more than thirty countries. This funding will be used to fuel its global expansion and further enhance its AI engine, tapping into a growing demand for data-driven dealmaking.
• Finally, we have two major fund launches rounding out the list. At number nine, Graduate Ventures announced the launch of its second seed fund, totaling one hundred thirty-two and a half million dollars, to invest in Dutch university spinouts. And at number ten, global life sciences VC Forbion has raised a staggering two-point-six billion dollars across two new funds. This represents one of the largest life sciences venture fundraisings globally in the last five years, giving Forbion immense firepower to back promising biotech and healthcare companies.
• Looking ahead, one thing to watch is the rise of AI-powered M&A. The seed round for Comparables.ai highlights this growing trend of integrating AI into corporate development. As dealmakers seek a competitive edge, platforms that can accurately map markets and identify targets are becoming essential. We'll be watching for more investment in this sector as both startups and established financial firms look to leverage AI for more efficient deal origination and execution. That's the deal flow for today. We'll be back tomorrow afternoon at three PM Pacific with the next Top Ten.